Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract

Damhofer, Helene; Ebbing, Eva A; Steins, Anne; Welling, Lieke; Tol, Johanna A; Krishnadath, Kausilia K; van Leusden, Tom; van de Vijver, Marc J; Besselink, Marc G; Busch, Olivier R; Henegouwen, Mark I van Berge; van Delden, Otto; Meijer, Sybren L; Dijk, Frederike; Medema, Jan Paul; van Laarhoven, Hanneke W; Bijlsma, Maarten F

doi:10.1186/s12967-015-0469-1

Table 2 Clinical and pathological characteristics of established xenograft models

From: Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract

ID	Gender	Age	Location	Stage (TNM)	Diagnosis	Diff. patient	Diff. xeno	Xeno take*	Cell lines	Treatment ⁺
PC028	F	74	liver metastasis	pTxNxM1	PDAC	moderate	moderate	4	yes	none
PC053M	M	78	liver metastasis	pTxN1M1	PDAC	moderate	poor	12	yes	none
PC053B	M	78	biopsy tumor	pTxN1M1	PDAC	na	poor	12	yes	none
PC067	F	73	resected tumor	pT3N1M0	PDAC	poor	moderate	26	yes	none
PC072	M	65	resected tumor	pT3N1M0	PDAC	moderate	moderate	24	no growth	none
PC076	M	64	resected tumor	pT3N1M0	PDAC	poor-moderate	moderate	33	yes	none
PC084	M	83	liver metastasis	pTxN1M1	PDAC	moderate-well	moderate	11	yes	none
PC086	M	66	resected tumor	pT4N1M0	PDAC	moderate	moderate	18	na	none
PC090	F	78	resected tumor	pT4N1M0	PDAC	moderate	well	19	yes	none
PC093	M	61	resected tumor	pT4N1M0	PDAC	moderate	moderate	37	ongoing	none
PC096	F	62	liver metastasis	pTxNxM1	PDAC	moderate	moderate	29	ongoing	none
PC099	F	46	liver metastasis	cT3NxM1	PDAC	well	moderate	23	ongoing	none
EAC007B	F	50	biopsy tumor	pT3N1M0	EAC	moderate	moderate-well	10	yes	none
EAC007R	F	51	resected tumor	pT3N1M0	EAC	moderate	poor-moderate	19	yes	chemoradiation
ESC008	F	37	resected tumor	pT4N0M0	ESC	moderate	poor-moderate	3	na	chemoradiation
EAC018	M	73	resected tumor	pT3N1M0	EAC	moderate	moderate-well	16	yes	chemoradiation
EAC023	M	58	biopsy tumor	pT3N2M0	EAC	poor	poor	14	yes	none
EAC026	M	69	lymph node metastasis	pT2N2M0	EAC	poor	poor	16	yes	chemoradiation
EAC027	M	66	adrenal gland metastasis	pT3NxM1	EAC	poor	poor	14	yes	radiation
EAC031B	M	78	biopsy tumor	pT3N3Mx	EAC	moderate	poor	14	yes	none
EAC031M	M	78	liver metastasis	pT3N3Mx	EAC	moderate	moderate	17	yes	chemotherapy
EAC033	M	54	liver metastasis	pT4N2M1	EAC	poor	poor	16	yes	chemotherapy
EAC037	M	68	thoracle TH metastasis	na	EAC	poor	poor	11	yes	chemotherapy
EAC038	M	76	lung metastasis	pT3N1M0	EAC	poor	poor	28	na	chemoradiation
ESC040	F	67	pelvis metastasis	pTxN2Mx	ESC	moderate	poor-moderate	17	ongoing	chemoradiation
EAC041	M	73	biopsy tumor	pTxN1M0	EAC	moderate	moderate	3	ongoing	none
ESC043	M	58	biopsy tumor	pT3N1Mx	ESC	na	moderate-well	10	na	none
ESC049	F	66	biopsy tumor	pT3N1M0	ESC	moderate	moderate	12	na	none
EAC050	M	69	biopsy tumor	pT3N2Mx	EAC	na	poor-moderate	11	na	none

*time in weeks required for the primary patient material to grow out and be retransplanted.
⁺neo-adjuvant treatment before resection.
Abbrevations: M male, F female, Diff. Differentiation grade, na not assessed due to limited or inconclusive material, PDAC pancreatic ductal adenocarcinoma, EAC esophageal adenocarcinoma, ESC esophageal squamous cell carcinoma.

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com

Journal of Translational Medicine

Contact us